Niki Karachaliou
Research Subjects
Research Interests
Niki Karachaliou has a total of 237 co-authors. Here are the top co-authors by number of shared publications:
- Rafael Rosell
Instituto Oncológico Dr. Rosell (IOR), Dexeus University Hospital, Barcelona, Spain
17 shared publications Rafael Rosell
Rosell Oncology Institute (IOR), Dexeus University Hospital, QuironSalud Group, 08028 Barcelona, Spain
16 shared publications- Andree Blaukat
Translational Innovation Platform Oncology and Immuno-Oncology, The Healthcare Business of Merck KGaA, Darmstadt, Germany
8 shared publications - Christopher Stroh
Companion Diagnostics & Biomarker Strategy, the healthcare business of Merck KGaA, Darmstadt, Germany
8 shared publications - Anderson Clark
Research Unit Oncology, EMD Serono Research and Development Institute, Inc., Billerica, Massachusetts
7 shared publications - Andreas Johne
Global Clinical Development, the healthcare business of Merck KGaA, Darmstadt, Germany
7 shared publications
Latest Publications
- Open Access
Understanding tumor adaptations and resistance to MET inhibitors in MET-altered non-small cell lung cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non–Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns
Pharmacological class and mechanism of new drugs approved by the U.S. FDA for use in NSCLC, January 2011 to December 2023
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non–Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns
Pharmacological class and mechanism of new drugs approved by the U.S. FDA for use in NSCLC, January 2011 to December 2023
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non–Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns
Pharmacological class and mechanism of new drugs approved by the U.S. FDA for use in NSCLC, January 2011 to December 2023
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non–Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns
Pharmacological class and mechanism of new drugs approved by the U.S. FDA for use in NSCLC, January 2011 to December 2023
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Data from Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non–Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns
Since 2011, the US FDA has approved 30 new drugs for use in advanced non–small cell lung cancer (NSCLC), mainly comprising tyrosine kinase inhibitors and immune checkpoint inhibitors. NSCLC with oncogene driver alterations is amenable to treatment with targeted drugs, usually small-molecule inhibitors. In these cases, the demonstration of high overall response rates, coupled with a lasting duration of response, has allowed for accelerated approval in the United States, based on single-cohort or multicohort trials. Confirmatory clinical evidence was subsequently provided through postmarketing trials. In NSCLC without such driver alterations, regulatory agencies in both the United States and the European Union set clinical evidence expectations that foster the conduct of studies primarily focused on determining survival or event-free survival, based on randomized controlled trial designs. This review analyzes the approval patterns of novel therapeutics for NSCLC with a focus on small-molecule inhibitors that target driver alterations, as well as biologics. The latter include mAbs inhibiting immune checkpoints like PD-(L)1 or cell surface receptors and antibody–drug conjugates, highly potent biologics linked to a cytotoxic compound. The differentiation of NSCLC into oncogene- and non–oncogene-addicted subtypes determines drug development strategies, the extent of the clinical development program, access to orphan drug development incentives, and regulatory approval strategies.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non–Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns
Since 2011, the US FDA has approved 30 new drugs for use in advanced non–small cell lung cancer (NSCLC), mainly comprising tyrosine kinase inhibitors and immune checkpoint inhibitors. NSCLC with oncogene driver alterations is amenable to treatment with targeted drugs, usually small-molecule inhibitors. In these cases, the demonstration of high overall response rates, coupled with a lasting duration of response, has allowed for accelerated approval in the United States, based on single-cohort or multicohort trials. Confirmatory clinical evidence was subsequently provided through postmarketing trials. In NSCLC without such driver alterations, regulatory agencies in both the United States and the European Union set clinical evidence expectations that foster the conduct of studies primarily focused on determining survival or event-free survival, based on randomized controlled trial designs. This review analyzes the approval patterns of novel therapeutics for NSCLC with a focus on small-molecule inhibitors that target driver alterations, as well as biologics. The latter include mAbs inhibiting immune checkpoints like PD-(L)1 or cell surface receptors and antibody–drug conjugates, highly potent biologics linked to a cytotoxic compound. The differentiation of NSCLC into oncogene- and non–oncogene-addicted subtypes determines drug development strategies, the extent of the clinical development program, access to orphan drug development incentives, and regulatory approval strategies.
- Open Access
- 23 August 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (21) , 4822-4833
Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non–Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns
Since 2011, the US FDA has approved 30 new drugs for use in advanced non–small cell lung cancer (NSCLC), mainly comprising tyrosine kinase inhibitors and immune checkpoint inhibitors. NSCLC with oncogene driver alterations is amenable to treatment with targeted drugs, usually small-molecule inhibitors. In these cases, the demonstration of high overall response rates, coupled with a lasting duration of response, has allowed for accelerated approval in the United States, based on single-cohort or multicohort trials. Confirmatory clinical evidence was subsequently provided through postmarketing trials. In NSCLC without such driver alterations, regulatory agencies in both the United States and the European Union set clinical evidence expectations that foster the conduct of studies primarily focused on determining survival or event-free survival, based on randomized controlled trial designs. This review analyzes the approval patterns of novel therapeutics for NSCLC with a focus on small-molecule inhibitors that target driver alterations, as well as biologics. The latter include mAbs inhibiting immune checkpoints like PD-(L)1 or cell surface receptors and antibody–drug conjugates, highly potent biologics linked to a cytotoxic compound. The differentiation of NSCLC into oncogene- and non–oncogene-addicted subtypes determines drug development strategies, the extent of the clinical development program, access to orphan drug development incentives, and regulatory approval strategies.
- 23 August 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (21) , 4822-4833
Open AccessTargeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non–Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns
Since 2011, the US FDA has approved 30 new drugs for use in advanced non–small cell lung cancer (NSCLC), mainly comprising tyrosine kinase inhibitors and immune checkpoint inhibitors. NSCLC with oncogene driver alterations is amenable to treatment with targeted drugs, usually small-molecule inhibitors. In these cases, the demonstration of high overall response rates, coupled with a lasting duration of response, has allowed for accelerated approval in the United States, based on single-cohort or multicohort trials. Confirmatory clinical evidence was subsequently provided through postmarketing trials. In NSCLC without such driver alterations, regulatory agencies in both the United States and the European Union set clinical evidence expectations that foster the conduct of studies primarily focused on determining survival or event-free survival, based on randomized controlled trial designs. This review analyzes the approval patterns of novel therapeutics for NSCLC with a focus on small-molecule inhibitors that target driver alterations, as well as biologics. The latter include mAbs inhibiting immune checkpoints like PD-(L)1 or cell surface receptors and antibody–drug conjugates, highly potent biologics linked to a cytotoxic compound. The differentiation of NSCLC into oncogene- and non–oncogene-addicted subtypes determines drug development strategies, the extent of the clinical development program, access to orphan drug development incentives, and regulatory approval strategies.
- Open Access
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Figure 2 from The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
Inhibition of MET phosphorylation and downstream signaling molecules with tepotinib in EBC-1 lung cancer cells (A; ref. 30) and Hs746T gastric cells (B; ref. 33). A, Adapted with permission from Bladt F, et al. Clin Cancer Res 2013;19 (11):2941–51. AKT, protein kinase B; ERK, extracellular signal-regulated kinase; Gab1, Grb2-associated binder 1; MET, mesenchymal–epithelial transition factor.
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
Inhibition of MET phosphorylation and downstream signaling molecules with tepotinib in EBC-1 lung cancer cells (A; ref. 30) and Hs746T gastric cells (B; ref. 33). A, Adapted with permission from Bladt F, et al. Clin Cancer Res 2013;19 (11):2941–51. AKT, protein kinase B; ERK, extracellular signal-regulated kinase; Gab1, Grb2-associated binder 1; MET, mesenchymal–epithelial transition factor.
- Open Access
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Figure 2 from The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
Inhibition of MET phosphorylation and downstream signaling molecules with tepotinib in EBC-1 lung cancer cells (A; ref. 30) and Hs746T gastric cells (B; ref. 33). A, Adapted with permission from Bladt F, et al. Clin Cancer Res 2013;19 (11):2941–51. AKT, protein kinase B; ERK, extracellular signal-regulated kinase; Gab1, Grb2-associated binder 1; MET, mesenchymal–epithelial transition factor.
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
Inhibition of MET phosphorylation and downstream signaling molecules with tepotinib in EBC-1 lung cancer cells (A; ref. 30) and Hs746T gastric cells (B; ref. 33). A, Adapted with permission from Bladt F, et al. Clin Cancer Res 2013;19 (11):2941–51. AKT, protein kinase B; ERK, extracellular signal-regulated kinase; Gab1, Grb2-associated binder 1; MET, mesenchymal–epithelial transition factor.
- Open Access
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Table 1 from The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
Summary table of completed and ongoing sponsor-initiated phase I and II clinical trials with tepotinib in patients with cancer.
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
Summary table of completed and ongoing sponsor-initiated phase I and II clinical trials with tepotinib in patients with cancer.
- Open Access
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Data from The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
The mesenchymal–epithelial transition factor (MET) proto-oncogene encodes the MET receptor tyrosine kinase. MET aberrations drive tumorigenesis in several cancer types through a variety of molecular mechanisms, including MET mutations, gene amplification, rearrangement, and overexpression. Therefore, MET is a therapeutic target and the selective type Ib MET inhibitor, tepotinib, was designed to potently inhibit MET kinase activity. In vitro, tepotinib inhibits MET in a concentration-dependent manner irrespective of the mode of MET activation, and in vivo, tepotinib exhibits marked, dose-dependent antitumor activity in MET-dependent tumor models of various cancer indications. Tepotinib penetrates the blood–brain barrier and demonstrates strong antitumor activity in subcutaneous and orthotopic brain metastasis models, in-line with clinical activity observed in patients. MET amplification is an established mechanism of resistance to EGFR tyrosine kinase inhibitors (TKI), and preclinical studies show that tepotinib in combination with EGFR TKIs can overcome this resistance. Tepotinib is currently approved for the treatment of adult patients with advanced or metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations. This review focuses on the pharmacology of tepotinib in preclinical cancer models harboring MET alterations and demonstrates that strong adherence to the principles of the Pharmacological Audit Trail may result in a successful discovery and development of a precision medicine.
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
The mesenchymal–epithelial transition factor (MET) proto-oncogene encodes the MET receptor tyrosine kinase. MET aberrations drive tumorigenesis in several cancer types through a variety of molecular mechanisms, including MET mutations, gene amplification, rearrangement, and overexpression. Therefore, MET is a therapeutic target and the selective type Ib MET inhibitor, tepotinib, was designed to potently inhibit MET kinase activity. In vitro, tepotinib inhibits MET in a concentration-dependent manner irrespective of the mode of MET activation, and in vivo, tepotinib exhibits marked, dose-dependent antitumor activity in MET-dependent tumor models of various cancer indications. Tepotinib penetrates the blood–brain barrier and demonstrates strong antitumor activity in subcutaneous and orthotopic brain metastasis models, in-line with clinical activity observed in patients. MET amplification is an established mechanism of resistance to EGFR tyrosine kinase inhibitors (TKI), and preclinical studies show that tepotinib in combination with EGFR TKIs can overcome this resistance. Tepotinib is currently approved for the treatment of adult patients with advanced or metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations. This review focuses on the pharmacology of tepotinib in preclinical cancer models harboring MET alterations and demonstrates that strong adherence to the principles of the Pharmacological Audit Trail may result in a successful discovery and development of a precision medicine.